Eagle Pharmaceuticals (EGRX) Tops Q4 EPS by 66c, Sales Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2016 Results
March 1, 2017 6:50 AM EST-- Bendeka® market share grew to 92% --
-- Bendeka reached $500 million in cumulative sales in Q1 2017, triggering $25 million milestone --
-- 2016 Revenue grew 186% to $189.5 million --
-- Q4 2016 income before tax benefit grew to $28.3 million, including $15.6 million of accelerated and non-recurring expenses
-- Q4 2016 EPS grew to $3.75 per basic and $3.52 per diluted share --
-- Full Year 2016 income before tax benefit grew to $53.4 million --
-- Full Year 2016 EPS grew to $5.24 per... More
